Almirall S.a.

BARCELONA, November 16, 2011 - Almirall's respiratory franchise continues to expand in COPD Clinical trials of the double bronchodilator combination have commenced to satisfy European and North American regulatory requirements Almirall, S.A.

STOCKHOLM, Sweden, October 24, 2011 - Full results from two Phase III linaclotide trials involving over 1,600 patients with irritable bowel syndrome with constipation (IBS-C) presented at the European Gastroenterology Week (UEGW) congress in Stockholm Linaclotide demonstrated significant improvement in abdominal pain/discomfort and degree of relief as well as quality of life[ii,iii] The estimated prevalence of IBS is 10-15% in the European population putting it in line with higher profile conditions such as migraine (12%) and asthma (11%).[iv] Almirall, S.A.

BARCELONA, Spain, September 29, 2011 - - Linaclotide has demonstrated statistically significant improvement in abdominal pain/discomfort and global relief of IBS-C symptoms in Phase III clinical trials [1,2] - IBS-C is a debilitating disease associated with reduced quality of life and considerable socio-economic and psychological consequences [3,4] Almirall, S.A.

AMSTERDAM, September 27, 2011 - Aclidinium DemonstratesImprovedLung Function, Symptom Controland Quality of LifeforChronic Obstructive Pulmonary Disease (COPD) Patients Almirall, S.A.

BARCELONA, July 27, 2011 - ? In clinical trials, aclidinium has shown 24-hour symptoms control, full bronchodilatory effect from the first day and tolerability similar to placebo Further details on the Phase III programme will be presented at theERScongress in September Almirall, S.A.